Atoa Coa Specifications: Ensuring Pharmaceutical-Grade Quality for (Z)-2-(2-Aminothiazole-4-yl)-2-[(trityloxy)imino]acetic Acid
- Comprehensive Certificate of Analysis (COA) includes identity confirmation, ≥98% assay by HPLC, and impurity profiling per ICH Q3 guidelines.
- Manufactured under cGMP with strict adherence to USP/ICH standards for pharmaceutical intermediates used in cefdinir synthesis.
- Bulk pricing and industrial-scale supply available for high-purity Z-ATOA with full regulatory documentation.
For pharmaceutical manufacturers sourcing (Z)-2-(2-Aminothiazole-4-yl)-2-[(trityloxy)imino]acetic acid (CAS 128438-01-7)—commonly known as ATOA, AT-TOA, or Z-ATOA—quality assurance begins with a robust Certificate of Analysis (COA). This critical intermediate in the synthesis route of the oral cephalosporin antibiotic cefdinir demands stringent control over purity, identity, and impurity profiles. When sourcing high-purity Z-ATOA, buyers must verify that every batch meets pharmaceutical-grade specifications through a complete, batch-specific COA issued by a qualified quality control laboratory.
Essential Analytical Data in ATOA Certificates of Analysis
A compliant COA for (2Z)-(2-amino-1,3-thiazol-4-yl)[(trityloxy)imino]ethanoic acid must include more than a simple “pass” statement. Per FDA 21 CFR 211.84 and ICH Q7, each COA must report actual numerical results for all tested parameters, linked to validated methods and authorized by qualified personnel. Key elements required in every ATOA COA include:
- Material Identification: Full chemical name, CAS number (128438-01-7), batch/lot number, manufacturing and retest dates, and grade designation (e.g., “Pharmaceutical Intermediate”).
- Test Parameters & Acceptance Criteria: Assay, related substances, residual solvents, water content, heavy metals, and microbial limits.
- Actual Results: Quantitative data—not qualitative summaries—for each test.
- Test Methods: References to compendial (USP, EP) or validated in-house procedures.
- QA Authorization: Signature or electronic approval from the quality unit.
Identity testing is mandatory for every incoming lot, regardless of supplier history, as stipulated under 21 CFR 211.84(d)(1). For Z-ATOA, this typically involves dual confirmation via HPLC retention time matching and FT-IR spectroscopy against a reference standard.
HPLC and NMR Criteria for ≥98% Purity Validation
The assay of ATOA is primarily determined by reverse-phase HPLC using a stability-indicating method. Our internal specifications require an assay of 98.0–102.0%, with typical batches achieving 99.5–100.3%. Impurity profiling is equally critical: total related substances must not exceed 1.5%, with no single unknown impurity above 0.3%.
Nuclear Magnetic Resonance (¹H NMR) is employed as a complementary identity and structural confirmation tool. The spectrum must show characteristic peaks at δ ~7.2–7.4 ppm (trityl aromatic protons), ~6.8 ppm (thiazole H-5), and ~5.6 ppm (imino proton), consistent with the (Z)-configuration. Absence of extraneous peaks confirms minimal process-related residuals.
Residual solvents are controlled per ICH Q3C, with limits for dichloromethane (<100 ppm), methanol (<300 ppm), and toluene (<890 ppm). Water content, measured by Karl Fischer titration, is held below 0.5% to ensure stability during storage and downstream reactions.
Typical COA Summary for Pharmaceutical-Grade ATOA
| Test Parameter | Specification | Typical Result | Method |
|---|---|---|---|
| Appearance | White to off-white crystalline powder | White crystalline powder | Visual |
| Identification (HPLC RT) | ±2% of reference | +0.6% | In-house M-HPLC-ATO-01 |
| Identification (FT-IR) | Concordant with reference | Concordant | USP <197K> |
| Assay (HPLC) | 98.0–102.0% | 99.8% | Validated RP-HPLC |
| Total Related Substances | NMT 1.5% | 0.7% | Stability-indicating HPLC |
| Water Content | NMT 0.5% | 0.32% | Karl Fischer (USP <921>) |
| Residual Solvents | Per ICH Q3C | All within limits | GC (USP <467>) |
| Heavy Metals | NMT 10 ppm | <5 ppm | ICP-MS (USP <232>/<233>) |
Meeting ICH and USP Standards for API Intermediates
As a key intermediate in cefdinir synthesis, ATOA falls under the scope of ICH Q7, which governs Good Manufacturing Practice for Active Pharmaceutical Ingredients. Our manufacturing process is fully cGMP-compliant, with rigorous in-process controls and final product release testing aligned with both ICH and relevant USP general chapters.
Microbial limits follow USP <61> and <62>, with Total Aerobic Microbial Count (TAMC) ≤100 CFU/g and Total Yeast and Mold Count (TYMC) ≤10 CFU/g—critical for non-sterile intermediates used in oral drug products. Endotoxin testing is not required unless specified for parenteral routes, but can be provided upon request.
Our industrial purity standards support seamless integration into large-scale cefdinir production. With multi-ton annual capacity and ISO 9001-certified operations, NINGBO INNO PHARMCHEM CO.,LTD. ensures consistent batch-to-batch quality, full traceability, and rapid delivery of high-purity ATOA worldwide.
For procurement teams evaluating suppliers, always request a full COA before qualifying a vendor. A legitimate COA will never substitute “conforms” for actual data—and will always include the lot number matching your shipment. Reduced testing programs are permissible only after documented supplier qualification and must still include identity testing on every lot.
In summary, when quality, compliance, and synthesis efficiency are paramount, choose a manufacturer that delivers not just high-purity Z-ATOA, but also transparent, regulation-ready documentation that supports your regulatory filings and manufacturing excellence.